The Medical Letter on Drugs and Therapeutics
In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
Download PDF:   US English
Med Lett Drugs Ther. 2022 May 16;64(1650):79
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
Upon completion of this activity, the participant will be able to:
  1. Review the efficacy and safety of the new higher dose of injectable semaglutide (Ozempic) for treatment of type 2 diabetes.
 Select a term to see related articles  Ozempic   Rybelsus   semaglutide   type 2 diabetes   Wegovy 

The FDA has approved a higher-dose injectable formulation of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic) for treatment of type 2 diabetes in adults. A single SC injection of the new 8 mg/3 mL formulation delivers 2 mg of semaglutide.

SEMAGLUTIDE FORMULATIONS — Ozempic has been available since 2018 in two multidose pens: one that delivers doses of 0.25 or 0.5 mg and one that delivers 1-mg doses (see Table 1). Up to 30% of patients treated with 1-mg doses of the drug do not achieve the desired A1C goal.1,2 An oral formulation of semaglutide (Rybelsus) has been available for treatment of type 2 diabetes since 2019.3 Injectable semaglutide is also available in a higher dose (2.4 mg) as Wegovy for chronic weight management in adults with or without type 2 diabetes who have a body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2 and at least one weight-related comorbidity.4

CLINICAL STUDIES — FDA approval of the new formulation was based on the results of a double-blind trial (SUSTAIN FORTE) in 961 patients with type 2 diabetes that was inadequately controlled on metformin with or without a sulfonylurea. Patients were randomized to receive semaglutide 1 or 2 mg SC once weekly. Patients in the 2-mg group had statistically significantly greater mean changes from baseline at 40 weeks in A1C (-2.2% vs -1.9%) and weight (-6.9 kg vs -6.0 kg) compared to those in the 1-mg group.5

ADVERSE EFFECTS — GI adverse effects (nausea, vomiting, diarrhea, constipation) are common with semaglutide. In SUSTAIN FORTE, GI adverse effects occurred in 34% of patients in the 2-mg group and in 31% of those in the 1-mg group. Acute pancreatitis and cholelithiasis have been reported with use of injectable and oral semaglutide. The labels of all semaglutide formulations include a boxed warning about a risk of thyroid C-cell tumors (based on animal data, no corroborating human data); the drug is contraindicated for use in patients with a personal or family history of medullary thyroid carcinoma and in those with multiple endocrine neoplasia syndrome type 2.

DOSAGE AND ADMINISTRATION — The starting dosage of Ozempic for treatment of type 2 diabetes is 0.25 mg injected SC once weekly in the abdomen, thigh, or upper arm. After 4 weeks, if tolerated, the dose should be increased to 0.5 mg. If additional glycemic control is needed, the dose can be doubled every 4 weeks to a maximum of 2 mg once weekly.

Unused pens should be stored in the refrigerator; after first use, they can be kept at room temperature for up to 56 days. A new needle should be attached for each injection and injection sites should be rotated each week. Ozempic does not need to be reconstituted before administration.

CONCLUSION — A 2-mg dose of the injectable GLP-1 receptor agonist semaglutide (Ozempic) has been approved by the FDA for use in patients with type 2 diabetes that requires additional glycemic control. In one clinical trial, addition of semaglutide 2 mg once weekly to standard treatment reduced A1C and weight more than addition of a 1-mg dose of the drug, but the effect was modest. GI adverse effects were common with both doses.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article